The first national drug price negotiations: 3 drugs fell by over half
Pilot work of State drug price negotiations for the first time have always aroused wide attention.
On May 20, the surging News (www.thepaper.CN) from national health planning Commission was informed that the first national drug price negotiation results are officially announced, involving two diseases 3 therapeutic, drop by more than half, and its neighboring countries (regions) convergence.
Among them, after first-line treatment for chronic hepatitis b drug tenofovir disoproxil negotiated prices compared with public hospitals before the purchase price of a decline of 67%, targeted therapy for non-small cell lung cancer drug IKE for dasatinib and gefitinib cuts amounted to 54% and 55%.
Why the national drug price negotiations lead in selecting these two diseases? State health planning agency Deputy Director, Division of drug supply management service said Cai Liping, currently, hepatitis remains one of our major communicable disease control key, heavy disease burden. The World Health Organization and our latest guideline-recommended first-line treatment for chronic hepatitis b oral drugs are tenofovir disoproxil and entecavir. Tenofovir disoproxil indications widely for the treatment of patients with chronic hepatitis b, has a good safety in pregnant women, and can be used for a variety of drug resistance in patients with chronic hepatitis b treatment. For the class of targeted drugs can conform to the indication of treatment of patients with non-small cell lung cancer with accuracy increase, lifetime extension. Against these two diseases in three drug price cuts, "to promote similar drug prices down to a reasonable interval. ”
Price savings on health care costs? B liver specialist, Beijing Ditan Hospital liver disease Xie Wen, Director of the Centre participated in the first national drug price negotiation, she rushes News (www.thepaper.CN), said that in China, chronic hepatitis b is a major cause of liver cirrhosis and liver cancer. Therefore, the timely and effective antiviral treatment is very necessary. Tenofovir disoproxil belong to patent medicines, before negotiations about 1500 Yuan monthly drug costs, post monthly drug costs down to approximately 490 Yuan. Entecavir (has patent original drugs) of the current monthly drug cost 820 Yuan.
"In 2016, surveys of chronic hepatitis b disease, nearly 30 million chronic hepatitis b patients in China, if they do not receive treatment likely to nearly 7 million people will develop cirrhosis or liver cancer, damage is huge in the future. And according to we national existing of data report, 30 million hepatitis b patients in the because various reasons, probably only 3 million of people in accept treatment, has 90% are no accept treatment, so if put all should accept treatment of patients cover came in words, according to 30 million people medication price 50% of conservative calculation, annual save of medical with can up 180 billion yuan, these people future if not development into cirrhosis or liver cancer, also will further save medical costs. "Xie Wen said.
Primary lung cancer (referred to as lung cancer) is one of the most common malignant tumors in China, first in the incidence of malignant tumors. Non-small cell lung cancer accounts for about 80% of all lung cancer, serious harm to people's health.
Shi yuankai, Deputy Director of Chinese Academy of medical sciences Cancer Hospital, said IKE for dasatinib, gefitinib is used for tumors of epidermal growth factor receptor (EGFR) sensitive mutation in patients with non-small cell lung cancer molecular-targeted drugs. Ecker for the monthly drug cost about 12000 Yuan before the negotiations, negotiations monthly drug costs fall to about 5500. Gefitinib in monthly drug costs before negotiations about 15000, post monthly drug costs down to approximately 7000 Yuan. "(Gefitinib) conservative estimate at least save 15 billion a year. "The Director of the Guangdong provincial people's Hospital of pulmonary Oncology Zhou Qing added.
State drug price negotiations result landed? National Health Planning Commission-news of the surging Drug Administration Director Zheng Hong, for guidance to implement the outcome of the negotiations as soon as possible to benefit patients, 7 departments jointly issued the negotiations on the national drug procurement notice. Around end of June will be the outcome of negotiations on provincial drug centralized purchasing platform, open mesh, medical institutions by negotiating prices purchasing directly on-line, to improve the scope of Medicare payment methods, do a pilot national drug negotiations and Medicare payment policies.
Reportedly, October 2015, by State approved, Wei Planning Commission, and NDRC, and Ministry, and commerce, and food drug prison General, 16 a ministries (Council) established has drug price negotiations Department inter joint system, Organization experts full Combs domestic patent drug, and exclusive production drug status, combined China major public health and disease control of medication needs, selection determine first negotiations drug, established negotiations group, developed negotiations process and strategy, synchronization established negotiations and supervision work mechanism. In late November last year, the first batch of State drug price negotiations officially started, the negotiating team met with hepatitis b, non-small cell cancer generic drugs companies have held several rounds of talks.
(Editors: Xu Yonggang UN006)
2016-05-20 13:21:35
Surging
首批国家药品价格谈判结果：3种药降幅超一半
首次国家药品价格谈判试点工作一直备受社会各方关注。
5月20日，澎湃新闻（www.thepaper.cn）从国家卫计委获悉，首批国家药品价格谈判结果正式公布，涉及两种疾病3种用药，降幅都在一半以上，与周边国家（地区）趋同。
其中，慢性乙肝一线治疗药物替诺福韦酯谈判后的价格与之前公立医院的采购价格相比降幅达67%，非小细胞肺癌靶向治疗药物埃克替尼和吉非替尼降价幅度分别达54%、55%。
首批国家药品价格谈判为何率先选择这两种疾病？国家卫计委药政司药品供应管理处副处长蔡丽萍介绍说，目前，病毒性肝炎仍是我国重大传染病防治重点之一，疾病负担较重。世界卫生组织和我国最新指南推荐的一线治疗慢性乙肝的口服药物是替诺福韦酯和恩替卡韦。替诺福韦酯对于慢性乙肝患者的治疗适应症广泛，对妊娠期妇女具有很好的安全性，且可用于各种耐药的慢性乙肝患者的治疗。替尼类靶向药物可使符合适应症的非小细胞肺癌患者治疗的精准性提高、生存期延长。而针对这两种疾病的三种药品的降价，“有利于促进同类药品价格降到合理区间。”
降价会节省多少医疗费用？乙肝病专家、北京地坛医院肝病中心主任谢雯参与了首批国家药品价格谈判，她向澎湃新闻（www.thepaper.cn）表示，在我国，慢性乙肝是导致肝硬化、肝癌的主要原因。因此，及时和有效的抗病毒治疗是非常必要的。替诺福韦酯属于专利药，谈判之前的月均药品费用约1500元，谈判后的月均药品费用降至约490元。恩替卡韦（已过专利期的原研药）目前月均药品费用约820元。
“2016年慢性乙肝病的调查报告显示，我国有接近3000万慢性乙肝病人，如果他们不接受治疗可能将近700万人会发展为肝硬化或肝癌，危害在将来是非常巨大的。而根据我们国家现有的数据报告，3000万乙肝病人中因为各种原因，大概只有300万的人在接受治疗，有90%都没有接受治疗，所以如果把所有应该接受治疗的病人覆盖进来的话，按照3000万人用药降价50%的保守计算，每年节省的医疗费用可达1800亿元，这些人将来如果不发展成肝硬化或肝癌，还会进一步节约医疗费用。” 谢雯说。
原发性肺癌（简称肺癌）是我国常见的恶性肿瘤之一，发生率居恶性肿瘤首位。非小细胞肺癌约占所有肺癌的80%，严重危害人民群众身体健康。
中国医科院肿瘤医院副院长石远凯介绍说，埃克替尼、吉非替尼等是用于肿瘤表皮生长因子受体（EGFR）敏感突变的非小细胞肺癌患者的分子靶向药物。埃克替尼谈判之前的月均药品费用约12000元，谈判后的月均药品费用降至约5500元。吉非替尼谈判之前的月均药品费用约15000元，谈判后的月均药品费用降至约7000元。 “（吉非替尼）保守估算一年至少节省150亿。”广东省人民医院肺部肿瘤科主任周清补充说。
国家药品价格谈判结果如何落地？国家卫计委药政司司长郑宏向澎湃新闻介绍，为指导各地抓紧落实谈判结果，尽快惠及广大患者，7部门联合印发《关于做好国家谈判药品集中采购的通知》。各地6月底前会将谈判结果在省级药品集中采购平台上公开挂网，医疗机构按谈判价格直接网上采购，要完善医保支付范围管理方法，做好国家药品谈判试点和医保支付政策衔接。
据悉，2015年10月，经国务院批准，卫计委、发改委、工信部、商务部、食药监总局等16个部委（局）建立了药品价格谈判部际联席会议制度，组织专家全面梳理国内专利药品、独家生产药品状况，结合我国重大公共卫生和疾病防治的用药需求，遴选确定首批谈判药品，成立谈判小组，制定谈判流程和策略，同步建立谈判和监督工作机制。去年11月下旬，首批国家药品价格谈判正式启动，谈判小组先后与乙肝、非小细胞癌症专利药品相关企业进行了多轮谈判。
(责任编辑：徐永刚 UN006)
2016-05-20 13:21:35
澎湃